Duke research could advance treatments for prostate cancer

A breakthrough coming out of Duke University has the potential to treat prostate cancer cells that have become impervious to hormone therapy – presenting a wealth of potential therapeutic benefits as researchers press forward.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news

Related Links:

This study included men who had undergone radical prostatectomy with neoadjuvant hormonal therapy between 2003 and 2016. We evaluated the association between clinicopathological factors and smoking status as well as the prognostic significance of smoking status in biochemical recurrence. The patients' backgrounds were comparable between smokers and nonsmokers. Smoking status were identified as significant risk factors of biochemical recurrence. Smoking was a risk factor of biochemical recurrence, suggesting that smoking may promote cancer recurrence after surgical treatment combined with hormonal therapy. PMID: 3301614...
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
(Kanazawa University) Kanazawa University researchers reported that the SUCLA2 gene is frequently involved in the deletion of the tumor suppressor gene RB1 in advanced prostate cancer. RB1 deletion makes cells resistant to hormone therapy but SUCLA2 deletion induces a metabolic weakness. The study showed that thymoquinone selectively killed SUCLA2-deficient prostate cancer cellsinvitro andinvivo. The findings highlight a vulnerability of advanced prostate cancer cells that can be targeted by drugs.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Conclusions: This is the first study to test sequence inversion for pelvic radio-chemotherapy in a randomized double-blind trial. Less chemotherapy interruptions or dose reductions occurred by inverting the radiation sequence of the large field and the boost.The trial was registered with Clinicaltrials.gov: NCT00452556
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Morphological and functional alterations of the prostate tissue during clinical progression in hormonally-naïve, hormonally-treated and castration-resistant patients with metastatic prostate cancer. Oncol Lett. 2020 Nov;20(5):201 Authors: KorĨek M, Sekerešová M, Makarevich AV, Gavurová H, Olexíková L, Pivko J, Barreto L Abstract Since commony used tools in oncological practice for the diagnosis of castration-resistent prostatic acinar adenocarcinoma are based on clinical criteria, such as castrate testosterone level, continuous rise in serum prostate-specific an...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Conclusions: Patients receiving hormonal treatment had significantly impaired HRQoL and survival compared with other treatments. Although the number of QALYs experienced was similar in the 3 other treatment lines, there were marked differences between treatment lines on some 15D dimensions.Urol Int
Source: Urologia Internationalis - Category: Urology & Nephrology Source Type: research
(Vall d'Hebron Institute of Oncology) Results from the PROfound phase III study open up a new treatment avenue for the more precise and effective treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed with hormonal therapy.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
This study aimed to investigate the risk of subsequent hypertension in patients undergoing androgen deprivation therapy for prostate cancer.Setting Data of 10,843 patients with prostate cancer were retrospectively collected from the Longitudinal Health Insurance Database of Taiwan. The institutional review board of Kaohsiung Medical University Hospital approved our study.Method In propensity score matching, 3001 patients with prostate cancer aged ≥ 40 years who underwent androgen deprivation therapy were included in the study cohort (androgen deprivation therapy-ever), and 3001 patients wi...
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
ConclusionsThese findings suggest an association between CYP17A1 c.-362T>C  polymorphism and poorer clinical outcome with abiraterone for mCRPC patients. However, further validations on larger cohort of patients are needed to confirm its role as a predictive biomarker for abiraterone resistance.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionSystematic screening in male SOTR after 50  years old could not be recommended. In the last 3 decades, we diagnosed too many low-risk prostate cancers strongly increasing the SIR but failing to decrease prostate cancer related mortality. SOTR should undergo individual screening with prior MRI when PSA rates are high. Management should not b e different from that of the general population.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
Authors: Cuccia F, Mazzola R, Nicosia L, Giaj-Levra N, Figlia V, Ricchetti F, Rigo M, Vitale C, Corradini S, Alongi F Abstract INTRODUCTION: To date, the optimal management of locally relapsed prostate cancer patients after an initial course of radiotherapy, remains a matter of debate. In recent years, local approaches have been proposed as a therapeutic option, which may potentially delay the initiation of hormone therapy. In the case of external beam radiotherapy (EBRT), re-irradiation has been supported by growing evidence in the literature, mostly represented by extreme hypofractionated schedules delivered with...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Health Management | Hormonal Therapy | Hormones | Prostate Cancer